SABR for Metastatic Cancers

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
London Health Sciences Centre- London Regional Cancer Program, London, Canada
Metastatic Cancers+1 More
Arm 2: SABR - Radiation
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a phase II/III international multicentre randomized trial. Patients will be randomized in a 1:2 ratio between the standard of care (Arm 1) and SABR (Arm 2) to all sites of disease. The study will start as a phase II trial with an opportunity to convert to a phase III trial. The objective of this trial is to determine the impact of SABR on overall survival, progression-free survival, quality of life, and toxicity in patients with polymetastatic disease.

Eligible Conditions

  • Metastatic Cancers

Treatment Effectiveness

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Time from randomization to death from any cause, patients followed for 5 years

Year 5
Toxicity of Ablative Radiotherapy
Year 5
Quality of life- An individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
Year 5
Overall Survival
Year 5
Progression-free survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

SABR
1 of 2
Standard of Care
1 of 2
Active Control

138 Total Participants · 2 Treatment Groups

Primary Treatment: SABR · No Placebo Group · Phase 2 & 3

SABR
Radiation
ActiveComparator Group · 1 Intervention: Arm 2: SABR · Intervention Types: Radiation
Standard of Care
Radiation
ActiveComparator Group · 1 Intervention: Arm 1: Standard of Care · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: time from randomization to death from any cause, patients followed for 5 years
Closest Location: London Health Sciences Centre- London Regional Cancer Program · London, Canada
Photo of ontario 1Photo of ontario 2Photo of ontario 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Metastatic Cancers
0 CompletedClinical Trials

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
607 Previous Clinical Trials
398,718 Total Patients Enrolled
2 Trials studying Metastatic Cancers
138 Patients Enrolled for Metastatic Cancers

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have histologically confirmed malignancy with evidence of metastatic disease on imaging.
Liver metastases must be confirmed by diagnostic or simulation MRI.
All sites of disease can be safely treated on a preliminary radiation plan.
PET/CT imaging is recommended, except for tumors where FDG uptake is not expected (e.g
A magnetic resonance imaging (MRI) of the brain is strongly recommended for all patients with known untreated or previously treated brain metastases

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.